2015
DOI: 10.1038/srep08712
|View full text |Cite
|
Sign up to set email alerts
|

Repetitive genomic insertion of gene-sized dsDNAs by targeting the promoter region of a counter-selectable marker

Abstract: Genome engineering can be used to produce bacterial strains with a wide range of desired phenotypes. However, the incorporation of gene-sized DNA fragments is often challenging due to the intricacy of the procedure, off-target effects, and low insertion efficiency. Here we report a genome engineering method enabling the continuous incorporation of gene-sized double-stranded DNAs (dsDNAs) into the Escherichia coli genome. DNA substrates are inserted without introducing additional marker genes, by synchronously … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 43 publications
0
1
0
Order By: Relevance
“…The stability of a plasmid in a carbon-limited fermentation, without selective pressure is largely governed by plasmid loss at division (segregational stability), with, on average, approximately 3% of a population becoming plasmid free in each generation [ 5 ]. Stabilisation of a pathway by genomic insertion is another method that has been widely studied [ 8 , 16 , 30 , 32 ]. It typically results in a lower gene dosage number, which can hinder product yields and extends R&D timescales by requiring insertion and subsequent quality control on every prototype pathway proposed.…”
Section: Introductionmentioning
confidence: 99%
“…The stability of a plasmid in a carbon-limited fermentation, without selective pressure is largely governed by plasmid loss at division (segregational stability), with, on average, approximately 3% of a population becoming plasmid free in each generation [ 5 ]. Stabilisation of a pathway by genomic insertion is another method that has been widely studied [ 8 , 16 , 30 , 32 ]. It typically results in a lower gene dosage number, which can hinder product yields and extends R&D timescales by requiring insertion and subsequent quality control on every prototype pathway proposed.…”
Section: Introductionmentioning
confidence: 99%